QL1706 Combined with Lenvatinib and GEMOX As First - Line Treatment for Unresectable Biliary Tract Tumors
QL1706 Combined with Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumorsï¼šA Single - Arm, Open - Label, Multi - Center, Prospective Phase II Clinical Trial (Spring Study)
Biliary Tract Tumors
DRUG: QL1706
Objective Response Rate (ORR), ORR was assessed by investigators per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)., Up to approximately 4 years
Disease Control Rate (DCR), DCR was assessed by investigators per RECIST 1.1, Up to approximately 4 years|Time to Response (TTR), TTR was assessed by investigators per RECIST 1.1, Up to approximately 4 years|Duration of Response (DOR), DOR was assessed by investigators per RECIST 1.1, Up to approximately 4 years|Progression-free Survival (PFS), PFS was assessed by investigators per RECIST 1.1, Up to approximately 4 years|12months-PFS rate, 12months-PFS rate was assessed by investigators per RECIST 1.1, 12 months|6months-PFS Rate, 6months-PFS Rate was assessed by investigators per RECIST 1.1, 6 months|Overall Survival (OS), OS was defined as the time from randomization to death due to any cause., Up to approximately 4 years|12months-OS Rate, 12months-OS Rate was assessed by investigators per RECIST 1.1, 12 months|24months-OS Rate, 24months-OS Rate was assessed by investigators per RECIST 1.1, 24 months|Incidence of Adverse Events (AEs), An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product., Up to approximately 4 years
This open - label, prospective, single - arm, multicenter phase II clinical study aims to assess the efficacy and safety of QL1706 combined with lenvatinib and GEMOX as first - line treatment for patients with unresectable biliary tract tumors.